Passage Bio to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
June 09 2022 - 7:30AM
Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic
medicines company focused on developing transformative therapies
for central nervous system disorders, today announced that Simona
King, chief financial officer of Passage Bio, will participate in a
fireside chat at the upcoming Goldman Sachs 43rd Annual Global
Healthcare Conference being held from June 13-16, 2022 in Rancho
Palos Verdes, CA.
Format: Fireside Chat Date:
Thursday, June 16, 2022Time: 8:40 a.m. PT (11:40
a.m. ET)
A live webcast of the event will be available on the Investors
& Media section of Passage Bio’s website at
investors.passagebio.com. A replay of the presentation will be
available for 30 days following the events.
About Passage Bio Passage Bio (Nasdaq: PASG) is
a clinical-stage genetic medicines company on a mission to provide
life-transforming therapies for patients with CNS diseases with
limited or no approved treatment options. Our portfolio spans
pediatric and adult CNS indications, and we are currently advancing
three clinical programs in GM1 gangliosidosis, Krabbe disease and
frontotemporal dementia with several additional programs in
preclinical development. Based in Philadelphia, PA, our company has
established a strategic collaboration and licensing agreement with
the renowned University of Pennsylvania’s Gene Therapy Program to
conduct our discovery and IND-enabling preclinical work. Through
this collaboration, we have enhanced access to a broad portfolio of
gene therapy candidates and future gene therapy innovations that we
then pair with our deep clinical, regulatory, manufacturing and
commercial expertise to rapidly advance our robust pipeline of
optimized gene therapies. As we work with speed and tenacity, we
are always mindful of patients who may be able to benefit from our
therapies. More information is available at www.passagebio.com.
For further information, please contact:
Investors:Stuart HendersonPassage
Bio267.866.0114shenderson@passagebio.com
Media:Mike BeyerSam Brown Inc. Healthcare
Communications312.961.2502MikeBeyer@sambrown.com
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Sep 2023 to Sep 2024